Segui
Simona Blotta
Simona Blotta
Medical Doctor, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy
Email verificata su ospedaleniguarda.it
Titolo
Citata da
Citata da
Anno
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
P Tassone, P Tagliaferri, A Perricelli, S Blotta, B Quaresima, ML Martelli, ...
British journal of cancer 88 (8), 1285-1291, 2003
4562003
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
J Rosenblatt, B Vasir, L Uhl, S Blotta, C MacNamara, P Somaiya, Z Wu, ...
Blood, The Journal of the American Society of Hematology 117 (2), 393-402, 2011
2592011
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
J Jakubikova, S Adamia, M Kost-Alimova, S Klippel, D Cervi, JF Daley, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4409-4419, 2011
1822011
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ...
Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012
1542012
RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma
AK Azab, F Azab, S Blotta, CM Pitsillides, B Thompson, JM Runnels, ...
Blood, The Journal of the American Society of Hematology 114 (3), 619-629, 2009
1402009
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
MA Shammas, H Koley, RC Bertheau, P Neri, M Fulciniti, P Tassone, ...
Leukemia 22 (7), 1410-1418, 2008
1272008
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma
J Jakubikova, D Cervi, M Ooi, K Kim, S Nahar, S Klippel, D Cholujova, ...
Haematologica 96 (8), 1170, 2011
932011
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
S Blotta, P Tassone, RH Prabhala, P Tagliaferri, D Cervi, S Amin, ...
Blood, The Journal of the American Society of Hematology 114 (15), 3276-3284, 2009
512009
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents
P Tassone, S Blotta, C Palmieri, S Masciari, B Quaresima, M Montagna, ...
International journal of oncology 26 (5), 1257-1263, 2005
332005
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma
P Neri, P Tassone, M Shammas, H Yasui, E Schipani, RB Batchu, S Blotta, ...
Leukemia 21 (12), 2519-2526, 2007
282007
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways
P Tagliaferri, P Tassone, S Blotta, C Viscomi, F Grillone, A Budillon, ...
Current Drug Targets 6 (3), 289-300, 2005
182005
In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells
P Neri, H Yasui, T Hideshima, P Tassone, N Raje, CP Laurence, ...
British journal of haematology 134 (1), 37-44, 2006
172006
Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma.
M Fulciniti, P Tassone, T Hideshima, S Vallet, S Ettenberg, D Stover, ...
Blood, The Journal of the American Society of Hematology 110 (11), 551-551, 2007
82007
A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.
G Gorgun, E Calabrese, M Mani, T Hideshima, H Ikeda, G Perrone, ...
Blood 112 (11), 1719, 2008
52008
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
AM Roccaro, IM Ghobrial, S Blotta, SP Treon, M Malagola, KC Anderson, ...
Biologics: Targets and Therapy 2 (3), 419-431, 2008
32008
Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial
G Martinelli, A Santoro, C Gambacorti-Passerini, SV Polo, SR Solomon, ...
J. Clin. Oncol 40 (7024), 10.1200, 2022
22022
Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical …
J Jakubikova, DN Cervi, JF Daley, D Cholujova, MG Ooi, S Klippel, ...
Blood 114 (22), 954, 2009
22009
TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.
R Prabhala, D Pelluru, P Neri, M Fulciniti, JJ Driscoll, S Weihua, S Blotta, ...
Blood, The Journal of the American Society of Hematology 110 (11), 3517-3517, 2007
22007
The novel, orally available multi-kinase inhibitor BAY 73-4506 in multiple myeloma
I Breitkreutz, MS Raab, O Christensen, A Zimmerhackl, J Zhang, S Blotta, ...
Blood, The Journal of the American Society of Hematology 112 (11), 2766-2766, 2008
12008
Waldenström macroglobulinemia: new therapeutic options
AM Roccaro, X Leleu, S Blotta, N Burwik, A Vacca, D Russo, IM Ghobrial
Cancer Therapy 6, 227-238, 2008
12008
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20